Dr. Karin Gaensler. Photo credit: Steve Babuljak/UCSF Adult acute myelogenous leukemia—also known as acute myeloid leukemia (AML)—is a blood cancer in which the bone marrow makes a large number of abnormal blood cells. About 20,000 new cases of AML are diagnosed each year in the US with a 5-year survival rate of around 29%. In … Continue reading Funding development of a vaccine for acute myelogenous leukemia (AML)
acute myeloid leukemia
How CIRM contributed to City of Hope study helping man with HIV into long-term remission
The news that a stem cell transplant at City of Hope helped a man with HIV go into long-term remission made banner headlines around the world. As it should. It’s a huge achievement, particularly as the 66-year-old man had been living with HIV since 1988. What wasn’t reported was that work supported by the California … Continue reading How CIRM contributed to City of Hope study helping man with HIV into long-term remission
CIRM-supported therapy for blood cancers gets FDA fast track
THIS BLOG IS ALSO AVAILABLE AS AN AUDIO CAST People often complain about how long it can take to turn a scientific discovery into an approved therapy for patients. And they’re right. It can take years, decades even. But for Immune-Onc Therapeutics the path to FDA approval may just have been shortened. Back in April … Continue reading CIRM-supported therapy for blood cancers gets FDA fast track
Paving the Way
When someone scores a goal in soccer all the attention is lavished on them. Fans chant their name, their teammates pile on top in celebration, their agent starts calling sponsors asking for more money. But there’s often someone else deserving of praise too, that’s the player who provided the assist to make the goal possible … Continue reading Paving the Way
CIRM Board Approves Clinical Trials for Blood Cancer and Pediatric Brain Tumors
Today the governing Board of the California Institute for Regenerative Medicine (CIRM) awarded $14.4 million for two new clinical trials for blood cancer and pediatric brain tumors. These awards bring the total number of CIRM-funded clinical trials to 70. $6.0 million was awarded to Immune-Onc Therapeutics to conduct a clinical trial for patients with acute … Continue reading CIRM Board Approves Clinical Trials for Blood Cancer and Pediatric Brain Tumors
CIRM-funded treatment for cancer granted FDA breakthrough therapy designation
Mark Chao, M.D., Ph.D., cofounder of Forty Seven, Inc. and current VP of oncology clinical research at Gilead Sciences An antibody therapeutic, magrolimab, being tested for myelodysplastic syndrome (MDS), a group of cancers in which the bone marrow does not produce enough healthy blood cells , was granted breakthrough therapy designation with the Food and Drug Administration … Continue reading CIRM-funded treatment for cancer granted FDA breakthrough therapy designation
Therapy developed with CIRM award used in new clinical trial for COVID-19
Dr. Joshua Rhein, Assistant Professor of Medicine in the University of Minnesota Medical School's Division of Infectious Diseases and International Medicine Image Credit: University of Minnesota While doctors are still trying to better understand how to treat some of the most severe cases of COVID-19, researchers are looking at their current scientific "toolkit" to see if … Continue reading Therapy developed with CIRM award used in new clinical trial for COVID-19
An off-the-shelf cancer killer
iPS Cell: Photo from the lab of Kathrin Plath at UCLA One of the hottest areas in cancer research right now is the use of CAR-T treatments. These use the patient’s own re-engineered immune system cells to target and kill the tumor. But the thing that makes it so appealing – using the patient’s own … Continue reading An off-the-shelf cancer killer
Four CIRM Funded Trials Release Results at 2019 ASH Meeting
With more than 17,000 members from nearly 100 countries, the American Society of Hematology (ASH) is an organization composed of clinicians and scientists around the world working to conquer various blood diseases. Currently, they are having their 61st Annual ASH Meeting to highlight some of the exciting work going on in the field. Four of … Continue reading Four CIRM Funded Trials Release Results at 2019 ASH Meeting
CIRM funded clinical trial shows promising results for patients with blood cancers
An illustration of a macrophage, a vital part of the immune system, engulfing and destroying a cancer cell. Antibody 5F9 blocks a "don't eat me" signal emitted from cancer cells. Courtesy of Forty Seven, Inc. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are both types of blood cancers that can be difficult to treat. CIRM … Continue reading CIRM funded clinical trial shows promising results for patients with blood cancers
The Stem Cellar 